TOWSON, MD and JERUSALEM, ISRAEL--(Marketwired - Apr 21, 2015) - LeukoDx Inc., an emerging leader in the field of innovative medical diagnostic technology, announced today the appointment of Dr. Tobias Volker as Senior Vice President for Commercial Operations. For the past 29 years, Dr. Volker has served in various positions in international sales and marketing, specifically in the field of life science and clinical diagnostics. Notably, he was Director of International Sales and Marketing and Strategic Alliances at Biosite from 1998 to 2005; under his guidance, the company successfully extended its Triage Cardiac and Triage BNP business globally. Since then, he has held the position of Director of international sales at Cholestech, and of Director of Commercial Operations at Quotient Diagnostics (now part of EKF Diagnostics). More recently, Dr. Volker was Senior Vice President at SK Telecom Healthcare Group. Dr. Volker holds a PhD in Biochemistry from the University of Bordeaux (France) and an MBA from INSEAD.

Julien Meissonnier, CEO of LeukoDx, said, "We are delighted that Dr. Volker is joining us at this critical phase of the commercialization of our first product. We are confident that his knowledge and experience with launches of new innovative biomarkers will drive our success in quickly establishing Accellix in the IVD marketplace."

Dr. Volker added, "LeukoDx has developed a marvel of a small, powerful flow cytometer, a truly disruptive technology which I am convinced will change how highly complex cytology tests will be managed in the future by making them simpler, faster and more accessible for everyone. We intend to release and commercialize the Accellix platform with an initial test for CD64, measuring host response in suspected sepsis patients. It will be a game-changing tool, helping laboratories provide these tests around the clock, reliably, and in a timely manner to emergency and critical care healthcare providers."

About LeukoDx Inc.

LeukoDx's mission is to deliver cost-effective, highly sensitive and actionable diagnostic information at the point of care via a novel automated IVD flow cytometry platform. Founded in 2009, LeukoDx's technology is based on technology initially developed for NASA at CalTech. To date, the Company has developed a compact reader for single use test-specific cartridges, and an application for the rapid confirmation of sepsis, a condition associated with high morbidity and mortality with no existing reliable diagnostic solution.

Contact Information:

Julien Meissonnier
President and CEO
Tel: +972-2-674-4422